Bcl-2 is a key member of the Bcl-2 family of proteins and is involved in the regulation of apoptosis. It was first discovered in a t(14:18) translocation and comprises the molecular hallmark of follicular lymphoma. The t(14:18)(q32;q21) chromosomal translocation results in a heterogeneous Bcl-2-immunoglobulin (Ig) chimeric gene. The translocated hybrid Bcl-2 -Ig gene has a high rate of transcription, resulting in overexpression of Bcl-2 mRNA and protein in cells possessing this translocation (Cleary et al., 1986; Bakhshi et al., 1987; Ngan et al., 1988; Petrovic et al., 1998) . Transgenic mice with Bcl-2 -Ig gene show high-grade B-cell lymphoma. This effect is tissue-specific for B cells (Petrovic et al., 1998) . Bcl-2 is overexpressed in a wide variety of cancers and autoimmune diseases (Cleary and Sklar, 1985; Cleary et al., 1986; Tsujimoto and Croce, 1986; Berghella et al., 1998) and has been implicated in the resistance of cancers to chemotherapy (Reed, 1999; Nicholson, 2000) .
The Bcl-2 family of proteins is divided into two major groups -antiapoptotic (Bcl-2, Bcl-xL, A1/BFl1, Mcl-1, Bcl-B, Bcl-W) and pro-apoptotic proteins (Bad, Bak, Bax, Bid). Pro-apoptotic Bcl-2 family proteins have been further classified based on the existence of Bcl-2 homology (BH) regions BH1 -4 (Huang and Strasser, 2000; Adams and Cory, 2001; Antonsson, 2001) . These BH regions mediate heterodimerization of pro-apoptotic proteins with antiapoptotic Bcl-2 proteins and thus regulate apoptosis in the cell (Chittenden et al., 1995; Zhang et al., 1995; Zha et al., 1996) . Bcl-2 has gained considerable interest as a potential target for the treatment of cancer. Different approaches, including antisense oligonucleotides, have been used to demonstrate the potential utility of targeting Bcl-2 (Cotter et al., 1994; Dias and Stein, 2002) . We have chosen to screen for small molecule antagonists of Bcl-2. To this end, the solution structure of Bcl-2 was determined . The molecule consists of a central, mostly hydrophobic a-helix surrounded by seven amphipathic a-helices, connected by loops of varying length. As was observed for Bcl-xL, helices 2, 3, 4, and 8 come together to form a hydrophobic groove on the surface of the protein. This groove is the binding pocket for the BH3 peptides. We found that rational design of potent BH3 peptide mimetics as small molecule inhibitors of Bcl-2 requires knowledge of the contribution of amino acids, in and around its binding groove, to BH3 peptide binding (Belli et al., 2003) . Specifically, two of the Bcl-2 sequences in Genbank -M13994 and M14745 -have a number of differences in their amino acids. Fesik and co-workers (Petros et al., 2001 ) studied two different Bcl-2 sequences -Bcl-2(1) and Bcl-2(2) -with amino-acid differences at positions 96 and 110. These are chimeric proteins in which the flexible loop of wildtype Bcl-2 was replaced by a shortened loop of Bcl-xL in order to improve the solubility of the proteins. Bcl-2(1) derived from M13994 has A96 and G110, whereas Bcl-2 (2), which is similar to M14745, has T96 and R110. The potential impact of these differences in the binding pocket is not immediately apparent from the structure of Bcl-2. Although the solution structures of these two Bcl-2 molecules are highly similar, they showed significant differences in binding affinity toward Bad and Bak BH3 peptides (Petros et al., 2001) . In addition, the relative contribution of these amino acids to binding is not known.
In view of the differences in the published Genbank sequences and also the differences in affinity between Bcl-2(1) and Bcl-2(2) with various peptides, we sought to address the question of what is the most common sequence in normal and cancer tissues. RT-PCR was performed on RNA isolated from normal and tumor tissues, and the product of PCR was purified and sequenced. The derived amino acid sequence was compared directly to the Genbank sequences of M13994 and M14745 clones. A comparison of the DNA sequence generated from tissues vs M13994 and M14745 revealed that the sequence in tissue samples did not match completely with either M13994 or M14745. Instead, the sequence had partial agreement with both genes. We observed five amino acid differences between these two sequences -at positions 59, 96, 110, 117 and 237.
The sequence in tissue samples agreed with the M14745 sequence at amino acids 96, 110 and 237, and with the M13994 sequence at 59 and 117 (Figure 1) . Table 1 summarizes the prevalence of the five amino acids in tissue samples compared to the three published sequences. It appears that the Bcl-2 sequence in tissues contains elements of the two published sequences for Bcl-2, and might be a combination of the sequences representing M13994 and M14745. The Bcl-2 sequence portion of the Bcl-2 -Ig fusion protein (accession number X06487) is identical to the tissue sample sequence in the binding pocket.
The deviation of amino acids in M13994 and M14745 compared to the Bcl-2 -Ig fusion gene bears further study, especially for the purpose of structure-activity studies and inhibitor design. The amino acid at position 59 is in the flexible loop and is not required for binding to the BH3 peptides. Similarly, amino acid residue 237 at the C-terminal region of the protein is involved in membrane association and is not involved in binding to apoptotic BH3 peptides (Muchmore et al., 1996; Sattler et al., 1997) . We do not know the effect of amino acid residue 117 on BH3 peptide binding. However, the two Bcl-2 clones that we tested had the same residue (serine) at position 117. BH3 peptide binding studies of Bcl-2(1) protein (A96G110), Bcl-2(2) protein (T96R110) and also a hybrid of the two Bcl-2 proteins (A96R110) allowed us to examine the importance of these two residues in binding to pro-apoptotic BH3 peptides. Substitution of glycine to a positively charged arginine at position 110 increased the binding affinity to the BH3 peptides by about 3 to 35-fold ( Figure 2b , Table 2 ). G110R substitution of Bcl-2(1) derived from M13994 results in binding affinity very close to Bcl-2(2). The similarity in binding affinity of A96R110 Bcl-2(1) to Bcl-2(2), which has threonine at position 96, indicates that amino acid 96 in the a2 helix is not important for binding to the proapoptotic BH3 peptides. The amino acid at position 110, on the other hand, is very important for binding and is solely responsible for the difference in affinity between Bcl-2(1) and Bcl-2(2). At position 110, Bcl-2(1) and Bcl-2(2) resemble M13994 and M14745, respectively. Based on our comparison of the two clones Bcl-2(1) and Figure 1 Comparison of the amino acid sequences of proteins derived from tissues and Genbank sequences. Sequence in tissue samples match that of X06487 at positions 59, 96, 110 and 117. The sequencing scheme that was employed did not allow analysis of codon 237 Normal and tumor breast or colon tissue was obtained from the Cooperative Human Tissue Network. RNA was isolated using the Qiagen RNeasy Maxi kit following recommended procedures. The region of the BCL2 mRNA of interest was amplified using the Invitrogen One-Step RT-PCR kit with primers BCL2-S (5 0 -CCGGGA-GATAGTGATGAAGTACAT) and BCL2-AS (5 0 -AAACAGCCTG-CAGCTTTGTTTCAT). PCR products were purified using Qiagen Qiaquick96 PCR purification system and sequenced using primer BCL-seq (5 0 -GGGCAGGCATGTTGACTTCACTT-3 0 ). 62 of 80 samples yielded PCR products that gave usable sequences. We were able to amplify BCL2 from breast tumor (23 of 24 tissues), colon tumor (24 of 24 samples) and normal colon (15 of 16 samples), but not normal breast tissues (16 samples). An alignment of the 62 sequences showed that codons 59 and 117 code for Pro and Ser, respectively, and thus are in agreement with the sequence from Accession number M13994. In contrast, codons 96 and 110 code for Thr and Arg, respectively, which agrees with the sequence in Accession M14745. All four positions agreed with the sequence in Accession number X06487. The sequencing scheme that was employed did not allow analysis of codon 237. In addition, not all samples generated readable sequence for codons 1-50. *nd ¼ not determined Bcl-2(2), changes such as that at position110 in the sequence of the Bcl-2 clones M13994 and M14745 will be expected to have substantial impact on the overall binding affinity of peptides and potential small molecule inhibitors. We found that a Bcl-2 preparation from R & D Systems (accession number P10415), which has identical sequence to X06487 in the binding pocket, binds with similar affinity to the BH3 peptides as Bcl-2(2) (data not shown).
In the structure of Bcl-2, arginine 110 is located on the a3 helix of the hydrophobic groove, but is oriented away from the groove and into solvent (Figure 2a) . It does not appear that this side chain would play a role in BH3 peptide binding. It is possible that binding of the BH3 region of pro-apoptotic proteins could result in a conformational change in Bcl-2. While the structure of a Bcl-2/BH3 peptide complex has not been determined, the binding of Bcl-xL to Bak and Bad peptides results in a conformational change in the binding groove (Sattler et al., 1997; Petros et al., 2000) . Bcl-xL has arginine at position 110 and binds with high affinity to BH3 peptides (Sattler et al., 1997) .
Structural information from Bcl-2 and Bcl-xL/peptide complexes, when used in conjunction with fluorescence anisotropy data enabled us to identify the role of amino acid residue(s) in the hydrophobic groove of Bcl-2, which would otherwise have not been possible with structural studies alone. Arginine 110 of Bcl-2 appears to be a key amino acid that positively impacts its binding to pro-apoptotic BH3 peptides. The solution structure does not highlight the involvement of this arginine as it is solvent exposed in the unbound form. Binding induced conformational change might be an important contributing factor. Information regarding intricate aspects of the binding pocket of Bcl-2 can be important in aiding the development of potent small molecule Bcl-2 inhibitors for the treatment of cancer (Belli et al., 2003) . (Zhang et al., 2002) . Briefly, fluorescein labeled BH3 peptides were incubated with serial dilutions of each of the Bcl-2 preparations in assay buffer consisting of 20 mM phosphate, 1 mM EDTA, 50 mM NaCI, 0.05% Pluronic F68 for 15 min. FP readings in millipolarization units were measured with an Analyst 96 well plate reader using an excitation wavelength of 485 nm and emission wavelength of 530 nm. Data were analysed for equilibrium dissociation constants (K d ) using Prism 3.0 software (Graphpad Software Inc., San Diego, CA, USA) by a sigmoid dose-response linear regression model Fluorescence Polarization studies were performed as described in Figure 2b using Bak BH3 peptide (GQVGRQLAIIGDK(FITC)-INR), Bad BH3 peptide (FITC-NLWAAQRYGRELRRMSDEFVDSFKK) and Bax BH3 peptide (FITC-QDASTKKLSECLKRIGDELDS-CONH2)
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